Evidence map›Paper›PMID 35898125›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2022

Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.

D M Kokebu, S Ahmed, R Moodliar, C-Y Chiang, G Torrea, A Van Deun, R L Goodall, I D Rusen, S K Meredith, A J Nunn

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

D M KokebuSt Peter´s Tuberculosis Specialised Hospital/Global Health Committee, Addis Ababa, Ethiopia.
S AhmedMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
R MoodliarTuberculosis & HIV Investigative Network (THINK), Doris Goodwin Hospital, Pietermaritzburg, South Africa.
C-Y ChiangDivision of Pulmonary Medicine, Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan, Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, International Union Against Tuberculosis and Lung Disease, Paris, France.
G TorreaInstitute of Tropical Medicine, Antwerp, Belgium.
A Van DeunInstitute of Tropical Medicine, Antwerp, Belgium.
R L GoodallMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
I D RusenResearch Division, Vital Strategies, New York, USA.
S K MeredithMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
A J NunnMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Instituut voor Tropische Geneeskunde · BEMRC Clinical Trials Unit at UCL · GBUniversity College London · GBInternational Union Against Tuberculosis and Lung Disease · FRVital Strategies · US

Funding

Medical Research Council MC_UU_00004/04Medical Research Council MR/J012513/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Tuberculosis, Multidrug-ResistantTuberculosis, PulmonaryAntitubercular AgentsHumansMaleRecurrenceRifampinTreatment OutcomeAntitubercular AgentsRifampin

Identifiers

PMID35898125
PMCPMC9341498
OpenAlexW4288074154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.